Shenzhen YHLO Biotech Co Ltd
SSE:688575
Intrinsic Value
Shenzhen YHLO Biotech Co., Ltd. engages in the research and development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay solution... [ Read More ]
The intrinsic value of one
Shenzhen YHLO Biotech Co Ltd
stock under the Base Case scenario is
25.76
CNY.
Compared to the current market price of 25.01 CNY,
Shenzhen YHLO Biotech Co Ltd
is
Undervalued by 3%.
Shenzhen YHLO Biotech Co Ltd's market capitalization is 14.2B CNY.
Shenzhen YHLO Biotech Co Ltd stock price is 25.01 CNY.
Shenzhen YHLO Biotech Co Ltd stock price (25.01 CNY) is 3% less than its Intrinsic Value (25.76 CNY).
Shenzhen YHLO Biotech Co Ltd stock (23.89 CNY) is 4% less than its price (25.01 CNY). Open DCF Valuation
Shenzhen YHLO Biotech Co Ltd stock price (25.01 CNY) is 9% less than its Relative Value (27.63 CNY). Open Relative Valuation
Shenzhen YHLO Biotech Co Ltd has upside potential of 9% compared to the average analyst price target.
Open Wall St Estimates
Shenzhen YHLO Biotech Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 11%.
Shenzhen YHLO Biotech Co Ltd has positive Net Debt. This means that the company has more debt (705m CNY) than cash and short-term investments (557m CNY).
Shenzhen YHLO Biotech Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 18%.
Shenzhen YHLO Biotech Co Ltd has negative Free Cash Flow for the last twelve months.
Shenzhen YHLO Biotech Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 22% to 11%.
Shenzhen YHLO Biotech Co Ltd has positive Net Income for the last twelve months.
Shenzhen YHLO Biotech Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 31% to 18%.
Shenzhen YHLO Biotech Co Ltd has positive Operating Income for the last twelve months.
Shenzhen YHLO Biotech Co Ltd's Revenue is forecast to fall at a rate of 11% per year over the next 3 years.
Shenzhen YHLO Biotech Co Ltd's Revenue has dropped by 31% over the past 12 months.
Shenzhen YHLO Biotech Co Ltd's short-term assets (2B CNY) exceed its short-term liabilties (879m CNY).
Shenzhen YHLO Biotech Co Ltd has very high three-year average ROIC (Return on Invested Capital): 26%. The company is very efficient at using invested capital to generate operating income.
Shenzhen YHLO Biotech Co Ltd has very high three-year average ROE (Return on Equity): 28%. The company is very efficient at transforming stockholders' equity into net income.
Shenzhen YHLO Biotech Co Ltd has positive Gross Profit for the last twelve months.
Shenzhen YHLO Biotech Co Ltd's long-term assets (4B CNY) exceed its long-term liabilties (1B CNY).
Shenzhen YHLO Biotech Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.28.
Shenzhen YHLO Biotech Co Ltd's Altman Z-Score is very high and is equal to 6.84.
Valuation Backtest
Shenzhen YHLO Biotech Co Ltd
Run backtest to discover the historical profit from buying and selling
Shenzhen YHLO Biotech Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shenzhen YHLO Biotech Co Ltd
Balance Sheet Decomposition
Shenzhen YHLO Biotech Co Ltd
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 557.2m |
| Receivables | 465m |
| Other Current Assets | 875.3m |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 288.9m |
| PP&E | 1.2B |
| Intangibles | 209.9m |
| Other Non-Current Assets | 122.6m |
| Current Liabilities | 878.7m |
| Accounts Payable | 199.3m |
| Accrued Liabilities | 58.9m |
| Short-Term Debt | 331.9m |
| Other Current Liabilities | 288.5m |
| Non-Current Liabilities | 404.4m |
| Long-Term Debt | 373.5m |
| Other Non-Current Liabilities | 30.8m |
Earnings Waterfall
Shenzhen YHLO Biotech Co Ltd
|
Revenue
|
2.4B
CNY
|
|
Cost of Revenue
|
-1.2B
CNY
|
|
Gross Profit
|
1.2B
CNY
|
|
Operating Expenses
|
-840.9m
CNY
|
|
Operating Income
|
355.1m
CNY
|
|
Other Expenses
|
69.1m
CNY
|
|
Net Income
|
424.2m
CNY
|
Free Cash Flow Analysis
Shenzhen YHLO Biotech Co Ltd
Profitability Score
Profitability Due Diligence
Shenzhen YHLO Biotech Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Shenzhen YHLO Biotech Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shenzhen YHLO Biotech Co Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Shenzhen YHLO Biotech Co Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shenzhen YHLO Biotech Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shenzhen YHLO Biotech Co Ltd
is 27.22 CNY
with a low forecast of 25.25 CNY and a high forecast of 31.21 CNY.
Shareholder Return
Price
Shenzhen YHLO Biotech Co Ltd
| Average Annual Return | -32.67% |
| Standard Deviation of Annual Returns | 20.65% |
| Max Drawdown | -67% |
| Market Capitalization | 14.2B CNY |
| Shares Outstanding | 568 308 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shenzhen YHLO Biotech Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Shenzhen YHLO Biotech Co., Ltd. engages in the research and development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay solution for diagnosis of autoimmune diseases, reproductive health, and infectious diseases. The company is headquartered in Shenzhen, Guangdong and currently employs 1,837 full-time employees. The company went IPO on 2021-05-17. The firm's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The firm's main products include in-vitro diagnostic instruments and supporting reagents based on chemiluminescence, immunoblotting, enzyme-linked immunoassay, immunofluorescence chromatography and other methodologies. The firm distributes its products in domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shenzhen YHLO Biotech Co Ltd
stock under the Base Case scenario is
25.76
CNY.
Compared to the current market price of 25.01 CNY,
Shenzhen YHLO Biotech Co Ltd
is
Undervalued by 3%.
You don't have any saved screeners yet
